Concepedia

Christof Vulsteke

CV

Statistics

Publications

50

Citations

7.2K

H-Index

26

Active since

2012

Affiliations

AZ Maria Middelares(Current)

University of Antwerp

Institut Gustave Roussy

Memorial Sloan Kettering Cancer Center

Merck & Co., Inc., Rahway, NJ, USA (United States)

Christof Vulsteke is an author at AZ Maria Middelares specializing in oncology, medicine, and chemotherapy.

ORCID

Publications per year

2012–2026

50

Publications

50

Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

Antonio González-Martı́n, Bhavana Pothuri, Ignace Vergote et al. · New England Journal of Medicine · 2019 · 2.3K citations · Full text

, , +15

Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma

Thomas Powles, Jonathan E. Rosenberg, Guru Sonpavde et al. · New England Journal of Medicine · 2021 · 1.2K citations · Full text

, , +14

Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer

Thomas Powles, Begoña P. Valderrama, Shilpa Gupta et al. · New England Journal of Medicine · 2024 · 914 citations · Full text

, , +14

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

Thomas Powles, Tibor Csőszi, Mustafa Özgüroğlu et al. · The Lancet Oncology · 2021 · 648 citations · Full text

, , +11

Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study

Robert L. Coleman, Domenica Lorusso, Christine Gennigens et al. · The Lancet Oncology · 2021 · 394 citations

, , +13

1–5 of 50